SalaryGuide
AboutPricingFor Employers

Marketing jobs

7 marketing jobs

Xeris Pharmaceuticals, Inc. logo
4 weeks ago

Associate Manager, Marketing - Neurology (Rare Disease)

Xeris Pharmaceuticals, Inc.

Chicago, IL (Hybrid)Full time$99K/yr – $120K/yr
Xeris Pharmaceuticals, Inc. logo
4 weeks ago

Senior Director, Pipeline Marketing Lead

Xeris Pharmaceuticals, Inc.

Chicago, IL (Hybrid)Full time$223K/yr – $268K/yr
Xeris Pharmaceuticals, Inc. logo
4 weeks ago

Associate Manager, Marketing – Endocrinology (Rare Disease)

Xeris Pharmaceuticals, Inc.

Chicago, IL (Hybrid)Full time$80K/yr – $140K/yr
Xeris Pharmaceuticals, Inc. logo
4 weeks ago

Associate Director, Marketing (Rare Disease)

Xeris Pharmaceuticals, Inc.

Chicago, IL (Hybrid)Full time$170K/yr – $190K/yr
Xeris Pharmaceuticals, Inc. logo
4 weeks ago

Associate Director, HCP Marketing (Rare Disease)

Xeris Pharmaceuticals, Inc.

Chicago, IL (Hybrid)Full time$140K/yr – $230K/yr
Xeris Pharmaceuticals, Inc. logo
7 weeks ago

Associate Manager, Marketing (Rare Disease)

Xeris Pharmaceuticals, Inc.

Chicago, IL (Hybrid)Full time$99K/yr – $120K/yr
Xeris Pharmaceuticals, Inc. logo
2 months ago

Associate Director, Marketing Rare Disease

Xeris Pharmaceuticals, Inc.

Chicago, IL (Hybrid)Full time$170K/yr – $195K/yr

All marketing roles in the US

Get alerts for this search

All marketing roles in the US

Get alerts for this search

7 jobs
Xeris Pharmaceuticals, Inc. logo

Associate Manager, Marketing - Neurology (Rare Disease)

Xeris Pharmaceuticals, Inc.

Chicago, IL (Hybrid)

$99K/yr - $120K/yrIn-houseFull-timeMid level3+ years exp.
4 weeks ago
Xeris Pharmaceuticals, Inc. logo

Senior Director, Pipeline Marketing Lead

Xeris Pharmaceuticals, Inc.

Chicago, IL (Hybrid)

$223K/yr - $268K/yrIn-houseFull-timeSenior level12+ years exp.
4 weeks ago
Xeris Pharmaceuticals, Inc. logo

Associate Manager, Marketing – Endocrinology (Rare Disease)

Xeris Pharmaceuticals, Inc.

Chicago, IL (Hybrid)

$80K/yr - $140K/yrIn-houseFull-timeMid level3+ years exp.
4 weeks ago
Xeris Pharmaceuticals, Inc. logo

Associate Director, Marketing (Rare Disease)

Xeris Pharmaceuticals, Inc.

Chicago, IL (Hybrid)

$170K/yr - $190K/yrIn-houseFull-timeDirector/executive8+ years exp.
4 weeks ago
Xeris Pharmaceuticals, Inc. logo

Associate Director, HCP Marketing (Rare Disease)

Xeris Pharmaceuticals, Inc.

Chicago, IL (Hybrid)

$140K/yr - $230K/yrIn-houseFull-timeSenior level8+ years exp.
4 weeks ago
Xeris Pharmaceuticals, Inc. logo

Associate Manager, Marketing (Rare Disease)

Xeris Pharmaceuticals, Inc.

Chicago, IL (Hybrid)

$99K/yr - $120K/yrIn-houseFull-timeMid level3+ years exp.
7 weeks ago
Xeris Pharmaceuticals, Inc. logo

Associate Director, Marketing Rare Disease

Xeris Pharmaceuticals, Inc.

Chicago, IL (Hybrid)

$170K/yr - $195K/yrIn-houseFull-timeSenior level8+ years exp.
2 months ago
Xeris Pharmaceuticals, Inc. logo
Xeris Pharmaceuticals, Inc.

Associate Manager, Marketing - Neurology (Rare Disease)

Chicago, IL (Hybrid)

$99K/yr – $120K/yrMid Level3+ years expFull time

Posted 4 weeks ago

Top 1% of applicants do these two things.

The other 99% submit and hope. You're about to do something different.

Job Summary

Own the end-to-end brand and promotional materials workflow, navigating MAP review, with cross‑functional playbooks to translate insights into HCP and patient tactics across digital and field channels.

  • MAP ownership: end-to-end materials lifecycle through Medical, Legal, Regulatory and Compliance reviews.
  • Cross-functional execution: translate customer insights into lifecycles and omni-channel campaigns.
  • Channel orchestration: support digital, field and non-personal tactics with compliant assets and training.

Job Description

Responsibilities

  • Partner with the Brand Lead to execute strategic and tactical marketing plans aligned with business objectives.
  • Support the development and implementation of HCP and patient marketing initiatives across personal, non-personal, digital, and field channels.
  • Collaborate with cross-functional stakeholders to translate customer insights into actionable marketing tactics and support lifecycle management initiatives.
  • Support sales force execution through development and maintenance of promotional materials, training support, and field pull-through initiatives.
  • Monitor brand performance, market trends, and competitive activity, providing recommendations for optimization and continuous improvement.
  • Lead the end-to-end management of promotional materials through Medical, Legal, Regulatory, and Compliance (MAP) review processes.
  • Conduct initial review of content to ensure alignment with brand strategy, messaging, claims, and visual identity.
  • Manage the development, approval, implementation, maintenance, expiration, and retirement of promotional materials.
  • Maintain the product claims library, reference repository, and promotional material inventory.
  • Partner with Marketing Centers of Excellence and agency partners to support digital channel execution, omnichannel initiatives, and content deployment.

Requirements

  • Bachelor’s degree in Marketing, Business, Communications, Life Sciences, or related field required.
  • MBA or advanced degree preferred.
  • Minimum 3–5 years of pharmaceutical, biotech, healthcare, or related commercial experience.
  • Rare disease experience preferred.
  • Demonstrated experience managing promotional review workflows through Medical, Legal, Regulatory, and Compliance processes.
  • Experience with Veeva PromoMats or similar content review systems required.
  • Working knowledge of FDA regulations, OPDP guidance, and pharmaceutical promotional compliance.
  • Demonstrated project management experience with multiple concurrent initiatives.
  • Experience managing agencies, vendors, budgets, timelines, and operational processes.
  • Familiarity with CRM and omnichannel marketing platforms.

Preferred

  • Experience with digital analytics tools and campaign attribution.
  • Experience partnering with patient advocacy groups.

Benefits

  • Comprehensive benefits package including paid time off benefits, various health, vision, and dental insurance options, 401(k) retirement benefits and more.
Xeris Pharmaceuticals, Inc. logo

Xeris Pharmaceuticals, Inc.

3.7 Glassdoor

We're a growth-oriented biopharmaceutical company improving patient lives by developing and commercializing advanced products across a range of therapies.

Founded in 2005
Chicago, Illinois, USA
445 employees (21 in marketing)
www.xerispharma.com
69% recommend to a friend
100% CEO approval

Traffic Signals

Monthly Visitors
7.9K
Traffic Source Mix
Search
37.1%
Direct
45.5%
Referral
7.1%
Social
8.8%
Paid
1.5%

Headcount Trend

Current headcount: ~445

Marketing Team

Marketing Team Size
19 (4% of company)
Marketing Roles Posted (Last 30 Days)
5

Funding

Total Funding
$548.5M
Last Raise
$200M
Post IPO Debt, 2 years ago

Funding History

  • Mar 2024
    Post IPO Debt • $200M
  • Jan 2022
    Post IPO Equity • $30M
  • Mar 2021
    Post IPO Equity • $27M

Recent News

A Look at Xeris Biopharma (XERS) Valuation After Patent Progress on Novel Hypothyroidism Therapy
Dec 2, 2025 • Sahm
Xeris Pharmaceuticals Secures Patent Allowance for XP-8121
Dec 1, 2025 • TipRanks
Xeris Biopharma (Nasdaq: XERS) receives USPTO Notice of Allowance for XP-8121
Dec 1, 2025 • Stock Titan
Xeris Biopharma Reports Strong Q3 2025 Financial Results
Nov 6, 2025 • TipRanks
Xeris Biopharma Posts Record Financial Results for the Third Quarter 2025
Nov 6, 2025 • Business Wire
Xeris Pharmaceuticals stock hits 52-week high at $10.03 By Investing.com
Nov 6, 2025 • Investing.com Nigeria
What Xeris Biopharma Holdings (XERS)'s Strong Revenue Growth and Pipeline Advances Mean For Shareholders
Oct 29, 2025 • Sahm
Xeris Biopharma Holdings (XERS): Evaluating Valuation After a Strong Share Price Rally
Oct 27, 2025 • Sahm
Has the Recent 166% Rally Left Xeris Biopharma Fully Priced in 2025?
Oct 25, 2025 • Sahm
Xeris Pharmaceuticals stock reaches 52-week high at $9.41
Oct 24, 2025 • Investing.com
Xeris Biopharma to Report Third Quarter 2025 Financial Results on November 6, 2025
Oct 23, 2025 • Business Wire
Xeris Biopharma Holdings, Inc.'s (NASDAQ:XERS) High Institutional Ownership Speaks for Itself as Stock Continues to Impress, up 13% Over Last Week
Oct 16, 2025 • 富途牛牛
Xeris Pharmaceuticals stock hits 52-week high at 8.53 USD
Oct 15, 2025 • Investing.com
Xeris Biopharma's Path Toward Profitability Might Change The Case For Investing In XERS
Oct 5, 2025 • Sahm
Xeris Biopharma Holdings, Inc. (XERS) Hits Fresh High: Is There Still Room to Run?
Oct 3, 2025 • Yahoo Finance
Xeris Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Oct 3, 2025 • Business Wire
Xeris Pharmaceuticals stock hits 52-week high at 8.36 USD
Oct 2, 2025 • Investing.com
Xeris Pharmaceuticals stock hits 52-week high at $8.03
Sep 18, 2025 • Investing.com
Xeris Biopharma Holdings, Inc.'s (NASDAQ:XERS) Shift From Loss To Profit
Sep 13, 2025 • 富途牛牛
Xeris Pharmaceuticals stock hits 52-week high at 8.02 USD
Sep 3, 2025 • Investing.com
Xeris Pharmaceuticals stock hits 52-week high at $7.96
Aug 26, 2025 • Investing.com
Patent Protection Until 2040: Xeris Adds Critical IP Shield for Rare Disease Drug Recorlev in FDA Orange Book
Aug 25, 2025 • Stock Titan
Xeris Biopharma receives new patent for Recorlev extending to 2040
Aug 25, 2025 • Investing.com
Xeris Announces Orange Book Listing of U.S. Patent for Recorlev®
Aug 25, 2025 • Business Wire
Xeris Pharmaceuticals stock hits 52-week high at $7.72
Aug 18, 2025 • Investing.com
Xeris Biopharma Holdings, Inc. (XERS) Hits Fresh High: Is There Still Room to Run?
Aug 12, 2025 • Yahoo Finance
Xeris Biopharma assumed with a Buy at H.C. Wainwright
Aug 12, 2025 • thefly.com
Xeris Pharmaceuticals stock hits 52-week high at 7.13 USD
Aug 11, 2025 • Investing.com
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Analysts Are Pretty Bullish On The Stock After Recent Results
Aug 10, 2025 • Sahm
Earnings call transcript: Xeris Pharmaceuticals beats Q2 2025 forecasts, stock surges
Aug 7, 2025 • Investing.com
Xeris Biopharma Reports Record Financial Results for the Second Quarter 2025 and Raises Full Year Revenue Guidance
Aug 7, 2025 • Business Wire
Xeris Biopharma Reports Record Financial Results for the Second Quarter 2025 and Raises Full Year Revenue Guidance
Aug 7, 2025 • BioSpace
Xeris Biopharma to Report Second Quarter 2025 Financial Results on August 7, 2025
Jul 31, 2025 • Business Wire
A Piece Of The Puzzle Missing From Xeris Biopharma Holdings, Inc.'s (NASDAQ:XERS) 25% Share Price Climb
Jul 15, 2025 • simplywall.st
Xeris Biopharma projects $1 billion Recorlev revenue by 2035
Jun 3, 2025 • Investing.com
Xeris Unveils Strategy for Long-Term Growth and Value Creation at 2025 Analyst & Investor Day
Jun 3, 2025 • Business Wire
Xeris Unveils Strategy for Long-Term Growth and Value Creation at 2025 Analyst & Investor Day
Jun 3, 2025 • MarketScreener
Xeris Biopharma Holdings Reaffirms 2025 Revenue Guidance Of $260-$275 Million
Jun 3, 2025 • MarketScreener
Earnings call transcript: Xeris Pharmaceuticals Q1 2025 revenue up 48%, stock rises
May 8, 2025 • Investing.com
Xeris Biopharma raises revenue guidance for 2025 to $260M-$275M amid strong Recorlev growth
May 8, 2025 • Seeking Alpha
Xeris Biopharma Reports Record First Quarter 2025 Financial Results
May 8, 2025 • MarketScreener
Xeris Biopharma Reports Record First Quarter 2025 Financial Results
May 8, 2025 • Morningstar.com
Xeris Biopharma to Report First Quarter 2025 Financial Results on May 8, 2025
May 1, 2025 • BioSpace
Analysts Expect Breakeven For Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Before Long
Apr 29, 2025 • simplywall.st
Xeris Biopharma Holdings, Inc.'s (NASDAQ:XERS) Shift From Loss To Profit
Apr 26, 2025 • Yahoo Finance
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Shares Acquired by Vanguard Group Inc.
Apr 15, 2025 • Defense World
Raymond James Financial Inc. Makes New Investment in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)
Apr 14, 2025 • Defense World
Global Subcutaneous Biologics Market to Surpass USD 236 Billion with Advancements in Self-Administration Devices and Drug Delivery Technologies
Apr 1, 2025 • Research and Markets
Xeris Pharmaceuticals (XERS) Announces Board Changes
Mar 28, 2025 • StreetInsider.com
Xeris Announces Changes to Its Board of Directors
Mar 28, 2025 • Business Wire
Xeris Announces Approval of Supplemental New Drug Application (sNDA) of Gvoke VialDx™ (glucagon) for Use as a Diagnostic Aid
Mar 17, 2025 • Business Wire
Xeris Pharmaceuticals Inc. (XERS) Announces Approval of Supplemental New Drug Application (sNDA) of Gvoke VialDx
Mar 17, 2025 • StreetInsider.com
Xeris Announces Approval of Supplemental New Drug Application (sNDA) of Gvoke VialDx™ (glucagon) for Use as a Diagnostic Aid
Mar 17, 2025 • BioSpace
Xeris Biopharma - Possibly The Best Pharma Stock
Mar 11, 2025 • Barchart
Xeris Pharmaceuticals stock hits 52-week high at $4.13
Mar 6, 2025 • Investing.com
Xeris Biopharma Delivers Record Fourth Quarter and Full-Year 2024 Results; and Announces 2025 Guidance
Mar 6, 2025 • Business Wire
Earnings call transcript: Xeris Pharmaceuticals Q4 2024 beats EPS forecast, stock surges
Mar 6, 2025 • Investing.com
Xeris Pharmaceuticals Inc. (XERS) Files $250M Mixed Shelf
Mar 6, 2025 • StreetInsider.com
Xeris Appoints Anh Nguyen, MD, MBA as Chief Medical Officer
Feb 24, 2025 • Business Wire
Xeris to Participate in Upcoming Investor Conferences
Feb 5, 2025 • BioSpace
The American Diabetes Association and Xeris Pharmaceuticals Announce National Collaboration to Provide Life-Saving Hypoglycemia Education and Awareness
Jan 21, 2025 • PR Newswire
Piper Sandler Downgrades Xeris Biopharma Hold...
Nov 11, 2024 • Benzinga
Xeris Biopharma price target raised by 60c at H.C. Wainwright, here's why
Nov 11, 2024 • thefly.com
Xeris Biopharma price target raised by 60c at H.C. Wainwright, here's why
Nov 11, 2024 • thefly.com
Xeris Biopharma Holdings: Promising Pipeline And Strategic Partnerships Make It Attractive
Oct 25, 2024 • Seeking Alpha
Xeris Biopharma And 2 Other Penny Stocks Insiders Are Buying
Aug 13, 2024 • TradingView
Xeris Biopharma announces CEO succession
Jul 11, 2024 • Crain's Chicago Business
Xeris Biopharma Announces CEO Succession Plan
Jul 10, 2024 • Business Wire
Xeris Biopharma Announces CEO Succession Plan
Jul 8, 2024 • Xeris Biopharma Holdings, Inc.
Xeris Biopharma Announces CEO Succession Plan
Jul 8, 2024 • BioSpace
Xeris stock jumps 14% on Phase 2 data for injected levothyroxine (NASDAQ:XERS)
May 30, 2024 • Seeking Alpha
Xeris to Participate in the Jefferies Global Healthcare Conference
May 30, 2024 • Business Wire
Xeris Biopharma Announces Positive Topline Phase 2 Clinical Data of Its Investigational XeriSol™-Formulated Once ...
May 29, 2024 • Business Wire
Xeris Enters Into an Exclusive Worldwide Collaboration and License Agreement with Beta Bionics
May 29, 2024 • Business Wire
Xeris Pharmaceuticals stock price target cut on Q1 results By Investing.com
May 29, 2024 • Investing.com
Xeris Biopharma to Report First Quarter 2024 Financial Results on May 9, 2024
May 2, 2024 • Business Wire
Post-Bariatric Hypoglycemia Market Poised for Growth by 2032, Projects DelveInsight | XOMA, Zealand Pharma A/S ...
Apr 26, 2024 • Barchart.com
Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Apr 3, 2024 • Business Wire
Xeris Pharmaceuticals shares target upgraded on expected revenue growth
Mar 29, 2024 • Investing.com
Xeris Pharmaceuticals, Inc. on LinkedIn: This is a presentation you won't want to miss! Xeris Chairman and CEO…
Jan 8, 2024 • LinkedIn
Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Jan 5, 2024 • Business Wire
Severe Hypoglycemia Treatment Market is Likely to Upsurge ...
Dec 9, 2023 • Artrocker
Xeris Biopharma Reports Third Quarter 2023 Financial Results
Nov 23, 2023 • Business Wire
Xeris Pharmaceuticals GAAP EPS of -$0.09 beats by $0.03, revenue of $48.32M beats by $7.24M
Nov 9, 2023 • SeekingAlpha
Xeris Biopharma Raises Full-Year Financial Guidance and Reaffirms Cash Flow Breakeven in Q4 2023
Oct 16, 2023
Xeris Biopharma Announces Private Convertible Note Exchange Transactions
Sep 27, 2023
Why Xeris Pharmaceuticals Is Soaring 7% Higher Today
Jan 1, 1970 • Yahoo Finance
Xeris Pharmaceuticals Completes Acquisition of Strongbridge Biopharma
Jan 1, 1970 • BioSpace
Xeris Pharmaceuticals Enters Collaboration Agreement With Merck
Jan 1, 1970 • Biospace
Xeris Pharmaceuticals Enters Into an Exclusive License and Supply Agreement with Tetris Pharma Limited to Commercialize Ogluo® in Europe
Jan 1, 1970 • Xeris Biopharma Holdings, Inc.
Xeris Pharmaceuticals reports Q2 revenue
Jan 1, 1970 • SeekingAlpha
Xeris Pharmaceuticals Stockholders Approve Acquisition of Strongbridge Biopharma
Jan 1, 1970 • BioSpace
Xeris Pharmaceuticals Completes Enrollment of Its Phase 1 Study of Levothyroxine (XP-8121)
Jan 1, 1970 • BioSpace
Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Jan 1, 1970 • PharmiWeb.com
Belay Diagnostics signs lease at Trammell Crow's Fulton Labs
Jan 1, 1970 • Urbanize Chicago